{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T17:30:22Z","timestamp":1688146222845},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"DOI":"10.2146\/ajhp140758","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T12:17:36Z","timestamp":1442578656000},"page":"1615-1622","source":"Crossref","is-referenced-by-count":9,"title":["Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease"],"prefix":"10.1093","volume":"72","author":[{"given":"Sally A.","family":"Arif","sequence":"first","affiliation":[{"name":"Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, and Clinical Pharmacist, Department of Pharmacy, Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Chicago College of Pharmacy, Midwestern University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rush University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna","family":"Gim","sequence":"additional","affiliation":[{"name":"Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, and Drug Information Specialist, Brookdale University Hospital and Medical Center, Brooklyn"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102112418500_b1-0721615","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041102112418500_b2-0721615","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041102112418500_b3-0721615","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1538-7836.2011.04277.x","article-title":"Atherothrombosis and the role of antiplatelet therapy","volume":"9","author":"Steg","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t2019041102112418500_b4-0721615","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","article-title":"2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non\u2013ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041102112418500_b5-0721615","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041102112418500_b6-0721615","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b7-0721615","article-title":"Chapter 30. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"Weitz","year":"2011","edition":"12th"},{"key":"key\n\t\t\t\t2019041102112418500_b8-0721615","first-page":"76","article-title":"Role of PAR-1 inhibitors in atherothrombosis","volume-title":"Therapeutic advances in thrombosis","author":"Moliterno","year":"2013","edition":"2nd"},{"key":"key\n\t\t\t\t2019041102112418500_b9-0721615","unstructured":"PubChem. Vorapaxar. http:\/\/pubchem.ncbi.nlm.nih.gov\/summary\/summary.cgi?cid=10077130&loc=ec_rcs (accessed 2014 Jul 23)."},{"key":"key\n\t\t\t\t2019041102112418500_b10-0721615","volume-title":"Zontivity (vorapaxar) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102112418500_b11-0721615","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019041102112418500_b12-0721615","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.jacc.2014.07.997","article-title":"New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2\u00b0P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041102112418500_b13-0721615","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2014.09.037","article-title":"Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2\u00b0 P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041102112418500_b14-0721615","first-page":"177","article-title":"Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar","volume":"10","author":"Cho","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t2019041102112418500_b15-0721615","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/eurheartj\/ehn027","article-title":"Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow\u2019s triad","volume":"29","author":"Yano","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041102112418500_b16-0721615","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"key\n\t\t\t\t2019041102112418500_b17-0721615","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1517\/14656561003720471","article-title":"Thrombin receptor antagonism: the potential of antiplatelet medication SCH 530348","volume":"11","author":"Macaulay","year":"2010","journal-title":"Exp Opin Pharmacother"},{"key":"key\n\t\t\t\t2019041102112418500_b18-0721615","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1476-5381.2009.00555.x","article-title":"Pharmacokinetic, pharmacodynamic, and clinical profile of novel antiplatelet drugs targeting vascular disease","volume":"159","author":"Siller-Matula","year":"2010","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b19-0721615","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/dmd.110.035493","article-title":"Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH530348 (vorapaxar), a potent oral thrombin protease-activated receptor I antagonist","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041102112418500_b20-0721615","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcph.20","article-title":"The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar","volume":"53","author":"Kosoglou","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b21-0721615","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"Angiolillo","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041102112418500_b22-0721615","first-page":"S21","article-title":"TRAP-induced platelet aggregation following single and multiple rising doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers","volume":"85","author":"Kosoglou","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041102112418500_b23-0721615","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jphs.08R06FM","article-title":"Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease","volume":"108","author":"Chintala","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"key\n\t\t\t\t2019041102112418500_b24-0721615","first-page":"564","article-title":"Vorapaxar: targeting a novel antiplatelet pathway","volume":"36","author":"Abdulsattar","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t2019041102112418500_b25-0721615","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00228-012-1269-7","article-title":"Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment","volume":"68","author":"Statkevich","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b26-0721615","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-012-1217-6","article-title":"Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b27-0721615","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00228-012-1271-0","article-title":"Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041102112418500_b28-0721615","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102112418500_b29-0721615","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102112418500_b30-0721615","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ahj.2014.09.002","article-title":"Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial","volume":"168","author":"Tricoci","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041102112418500_b31-0721615","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041102112418500_b32-0721615","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102112418500_b33-0721615","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standarized bleeding definitions for cardiovascular clinical trials","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041102112418500_b34-0721615","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cpdd.49","article-title":"Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT\/QTc interval in healthy volunteers: a randomized, placebo- and positive-controlled, parallel group trial","volume":"3","author":"Kosoglou","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key\n\t\t\t\t2019041102112418500_b35-0721615","volume-title":"Red Book Online [online database]"},{"key":"key\n\t\t\t\t2019041102112418500_b36-0721615","unstructured":"European Medicines Agency. Vorapaxar. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/pips\/EMEA-000778-PIP02-12\/pip_001090.jsp&mid=WC0b01ac058001d129 (accessed 2014 Oct 10)."},{"key":"key\n\t\t\t\t2019041102112418500_b37-0721615","unstructured":"ClinicalTrials.gov. Trial to assess the safety of vorapaxar in Japanese subjects with cerebral infarction. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00684515 (accessed 2015 Jul 25)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/19\/1615\/28339001\/ajhp1615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T14:48:08Z","timestamp":1567176488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/19\/1615\/5111448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140758","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,10,1]]},"published":{"date-parts":[[2015,10,1]]}}}